This case shows that a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without widespread toxicity.

Long-awaited results from phase III trial show a huge benefit in treating treatment-resistant melanoma.

Early trial results suggest invikafusp alfa may help control some advanced cancers resistant to immunotherapy. Learn what researchers found and what remains unknown.

iOnctura is set to present critical findings regarding roginolisib in treating immunotherapy-resistant NSCLC at SITC 2026, highlighting its innovative approach.

New study supports use of hormone therapy followed quickly by immunotherapy for prostate cancers, which are largely resistant to immunotherapies.

Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.

Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.

At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.

Long-awaited results from phase III trial show a huge benefit in treating treatment-resistant melanoma.

Engineered inhalable exosomes deliver a bispecific T cell activator to pembrolizumab-resistant metastatic melanoma.

Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.

Experimental drug invika halts progression of refractory tumors by selectively stimulating tumor-fighting T cells. Image Sullivan, Tschernia, Friedman, et al. Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the pioneering treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy. A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham and Memorial Sloan Kettering found that, at optimal doses, invika was well tolerated and, in patients whose solid tumors had resisted standard immunotherapy, halted disease progression in most and shrank tumors in some. “Patients whose tumors are advanced — particularly tumors that don’t respond well to immunotherapy — often have their backs against a wall. Few options remain once you reach that point, but these results highlight a more precise means of stimulating anti-tumor immunity that could provide another solution,” said co-corresponding author James Gulley, M.D., Ph.D., clinical director at the Center for Cancer Research (CCR), part of NIH’s National Cancer Institute (NCI). While immunotherapies have already transformed treatment for several cancers, many patients benefit from them for only a short time, or not at all. Tumors frequently adapt...

Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.

UK scientists find tocilizumab, commonly used for rheumatoid arthritis, may help antidepressant-resistant patients

Research suggests that inflammation plays a role in treatment-resistant depression (TRD). Scientists tested an immunotherapy drug in patients with low-grade inflammation and TRD. Early signals suggest...

Polymer-based nanomedicines could reshape the tumor microenvironment, helping immune cells attack resistant cancers and potentially improve immunotherapy.

Read the full paper: Chromatin accessibility trajectories reveal pre-cancerous epigenetic priming and an acid-driven immunotherapy-resistant gastric cancer subtype

Wang et al. build a chromatin accessibility atlas of 650 gastric tissue samples spanning pre-cancer to advanced cancer, revealing a cancer-like epigenetic priming state in metaplasia that licenses tumor initiation. Advanced cancers segregate into three epigenomic subtypes; the pseudo-gastric subtype resists immunotherapy via FOSL2-driven H+/K+ ATPase expression that acidifies the microenvironment and suppresses CD8+ T cells—a phenotype reversed by the acid blocker vonoprazan.

GOOD NEWS! A new cancer treatment has demonstrated unprecedented results in a large trial for cancer patients whose disease has become resistant to chemotherapy AND immunotherapy. Tumors shrank in OVE...